Delbert Pharma

Acquired in 2013 and managed since by psychiatrist and pharmacist Dr. Marc Childs and Dr. Thierry Hoffmann, Delbert Pharma is specialized in acquiring and keeping on the market drugs with essential or major therapeutic interests as defined by the World Health Organization.

Exercising in three main therapeutics areas (infectiology, nervous system and oncology), Delbert Pharma has a renown know-how in securing the production line enabling to reduce supply risks and to impose itself as the reference partner for reglementary bodies and big pharma. Those skills also enabled the company to develop orphan drugs repositioning already existing molecules on the market.

Relying on its expertise and its network in the healthcare sector, Vivalto Partners is willing to support Delbert Pharma in a new stage of development allowing their international reinforcement and the development of drugs in new therapeutics areas. Moreover, like Vivalto Santé, Delbert Pharma has chosen to be a B corporation.

« We are delighted to welcome Vivalto Partners, a new financial partner specialized in the sector and with a strong entrepreneurial spirit. With the management team and our historical shareholders (Sagard NewGen, Socadif Capital Investment, IDIA Capital Investissement et MACSF) whom are continuing the adventure that started 3 years ago, we will be able to reach a new milestone et keep sticking to our vocation: providing access to essential medicines abandoned by the market to all patients and make reborn and reuse pharmaceuticals specialties for the benefit of all. »

Marc Childs and Thierry Hoffmann, directors of Delbert Pharma